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high mobility group box-1 protein in vitro and the subsequent 
upregulation of proinflammatory cytokines such as interleu-
kin (Il) 1β, Il6 and Il18 in vivo. animals cured by ltX-315 
treatment were protected against a re-challenge with live B16 
tumor cells both intradermally and intravenously. together, our 
data indicate that intratumoral treatment with ltX-315 can 
provide local tumor control followed by protective immune 
responses and has potential as a new immunotherapeutic agent.
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Abbreviations
aCPs  anticancer peptides
CaPs  Cationic antimicrobial peptides
DaMPs  Danger-associated molecular pattern molecules
DCs  Dendritic cells
HMgB1  High mobility group box-1




lfcinB  Bovine lactoferricin
Mtt  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zodium bromide
nK  natural killer cells
Sar  Structure–activity relationship
tIls  tumor-infiltrating lymphocytes
Introduction
Malignant melanoma, which develops from a neoplastic 
transformation of melanocytes, is the most aggressive form 
Abstract Malignant melanoma is the most aggressive and 
deadliest form of skin cancer due to its highly metastatic poten-
tial, which calls for new and improved therapies. Cationic anti-
microbial peptides (CaPs) are naturally occurring molecules 
found in most species, in which they play a significant role in 
the first line of defense against pathogens, and several CaPs 
have shown promising potential as novel anticancer agents. 
Structure–activity relationship studies on the CaP bovine 
lactoferricin allowed us to de novo design short chemically 
modified lytic anticancer peptides. In the present study, we 
investigated the in vivo antitumor effects of ltX-315 against 
intradermally established B16 melanomas in syngeneic mice. 
Intratumoral administration of ltX-315 resulted in tumor 
necrosis and the infiltration of immune cells into the tumor 
parenchyma followed by complete regression of the tumor 
in the majority of the animals. ltX-315 induced the release 
of danger-associated molecular pattern molecules such as the 
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of skin cancer, and the number of incidents has increased 
annually by 2.8 % since 1981 in the US alone [1]. With 
the increase in the number of patients, the need for new 
and improved therapies is prevalent. Standard treatment 
includes surgery, chemotherapy, immunotherapy and radia-
tion therapy [2, 3], while the prognosis and treatment given 
depends on at which stage the melanoma is diagnosed 
(Stage I, II, III or IV). Melanomas that have not spread 
beyond their site of origin are highly curable; however, the 
difficulties linked to treatment increase considerably once 
the melanoma metastasizes, thus leading to a poor survival 
rate [4]. Improvements in treatment regimens have primar-
ily been within immunotherapy, as demonstrated by the 
approval of Ipilimumab (Yervoy™; Bristol-Myers Squibb, 
USa) in 2011. together with ongoing research on targeted 
therapy, there is an increasing focus on the development of 
new immunotherapeutic drugs [5, 6].
Cationic antimicrobial peptides (CaPs) are naturally 
occurring molecules found in a number of species as a 
defense mechanism for eukaryotic cells against pathogens 
and are an integral part of the innate immune system [7]. 
although there is a vast variation between CaPs when it 
comes to features such as amino acid sequence and sec-
ondary structure, they are normally cationic and amphip-
athic, which enables them to interact with lipid membranes. 
CaPs have a broad spectrum of activities such as anti-
microbial, anticancer or both, while being less cytotoxic 
toward non-malignant cells. nevertheless, some CaPs 
are non-selective and display cytotoxic activity against 
microbes and cancer cells, as well as normal mammalian 
cells [8]. the potential therapeutic application against can-
cer has spawned an interest in developing anticancer agents 
that display a new mode of action to overcome the potential 
drug resistance associated with other current therapeutics. 
the anticancer effects of CaPs are still under investiga-
tion, but several peptides have already exhibited a promis-
ing potential with cytotoxic activities against a broad spec-
trum of tumor cells [9–12]. CaPs with the ability to kill 
cancer cells are typically referred to as anticancer peptides 
(aCPs). the anticancer activity of aCPs is exerted through 
either a membranolytic mode of action or through an inter-
action with intracellular targets, or a combination of the 
two. aCPs bind to cancer cell membranes through elec-
trostatic interactions between the positively charged pep-
tide and the anionic cancer cell membrane, thereby lead-
ing to a destabilization and disruption of the membrane. 
the upregulated expression of anionic molecules such as 
phosphatidylserine [13], sialic acid on glycoproteins [14] 
and heparan sulfate on proteoglycans [15, 16] on cancer 
cell membranes results in a higher net negative charge 
compared to non-malignant eukaryotic cells. this may help 
explain why aCPs usually have a higher specificity toward 
certain tumor cells compared to normal eukaryotic cells. 
additional factors that may contribute to the selective kill-
ing of cancer cells by aCPs include membrane fluidity and 
cell surface area. Compared to non-malignant cells, cancer 
cells often have a greater membrane fluidity [17, 18] and 
cell surface area (additional microvilli) [19, 20], hence 
leading to an improved anticancer activity of aCPs due to 
an increased membrane destabilization and the ability to 
bind more aCP molecules. Moreover, aCPs kill both drug-
sensitive and drug-resistant cancer cells due to their mem-
branolytic mode of action, independently of proliferative 
status and resistance phenotype [21, 22].
Bovine lactoferricin (lfcinB), which is one of the most 
widely studied CaPs, has been reported to induce necrosis 
[23, 24] and apoptosis [25, 26] in vitro, as well as having 
direct antitumor effect in vivo. Both the systemic admin-
istration and intratumoral (i.t.) administration of lfcinB 
have been shown to inhibit tumor growth and metastasis in 
several experimental mouse models [23, 24, 27]. Structure–
activity relationship (Sar) studies on lfcinB have enabled 
us to reveal structural parameters critical for antitumor 
activity, thus leading to the discovery of more potent aCPs 
[28–32], including the nonapeptide ltX-315. Similar to 
many aCPs, ltX-315 has the potential to adopt a helical 
coil structure (predicted by the garnier-Osguthorpe-rob-
son V method [33] ). In order to explore the mode of action 
of ltX-315 in more detail, we investigated the anticancer 
activities of ltX-315 against a selection of murine and 
human cancer cell lines in vitro and following i.t. adminis-
tration against murine melanomas (B16F1) in vivo.
Materials and methods
reagents
ltX-315 (K-K-W-W-K-K-W-Dip-K-nH2) and ltX-328 
(K-a-Q-Dip-Q-K-Q-a-W-nH2) were purchased on request 
from Bachem ag (Bubendorf, Switzerland) and Innovagen 
(lund, Sweden), respectively.
Dacarbazine (D2390), temozolomide (t2577) and cis-
diammineplatinum dichloride (P4394) were all purchased 
from Sigma-aldrich.
Cell lines
B16F1 (atCC, Crl-6323), a skin malignant melanoma 
of C57Bl/6 murine origin, MrC-5 (atCC, CCl-171), a 
human embryonic lung fibroblast cell line and HUV-eC-C 
(atCC, Crl-1730), a human umbilical vein endothelial 
cell line, were all purchased from the american type Cul-
ture Collection (atCC-lgC Standards, rockville, MD, 
USa). a375 (eCaCC, 88113005) is a human malignant 
melanoma derived from patient material purchased from 
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Public Health england (PHe Culture Collections, Porton 
Down, Salisbury, UK). B16F1 and a375 cells were cul-
tured in DMeM (high glucose) and MrC-5 cells in MeM 
(normal glucose) containing 2 mM l-glutamine (all) and 
1 % non-essential amino acids (a375 only). Primary epi-
dermal melanocytes (atCC, PCS-200-013) were cultured 
in Dermal Basal Medium (atCC, PCS-200-030) supple-
mented with the adult Melanocyte growth Kit (atCC, 
PCS-200-042). HUV-eC-C was cultured using the egM-2 
BulletKit from lonza, and all growth media were with-
out antibiotics and supplemented with 10 % FBS (except 
serum-free primary melanocytes). Cell cultures were main-
tained in a humidified atmosphere of 5 % CO2 and >95 % 
humidity at 37 °C and tested for either both mycoplasma 




nyltetrazodium bromide (Mtt) viability assay [34] was 
employed to assess the in vitro cytotoxicity of ltX-315 
and ltX-328 (B16F1 only) against a selection of both can-
cer cells and non-malignant cells. Pre-cultured cells were 
transferred to a 96-well plate in subconfluent concentra-
tions at a volume of 100 μl/well (culture media). adher-
ent cells were left overnight in a cell incubator under 
37 °C, >95 % humidity and 5 % CO2 conditions, and all 
wells were plated in triplicate. ltX-315 and ltX-328 were 
dissolved in serum-free rPMI 1640 and diluted to a con-
centration range of 7–350 μM. Cells were washed once 
with serum-free rPMI 1640 before being incubated with 
peptide solutions for 4 h. Cells in serum-free media alone 
were used as a negative control, while cells treated with 
1 % triton X-100 (Sigma-aldrich) in a serum-free media 
as positive controls. a 10 μl Mtt solution (5 mg Mtt per 
ml phosphate buffered saline) was added to each well, and 
the incubation was continued for an additional 2 h. Seventy 
microliters of solution were removed from each well, and 
100 μl of 0.04 M HCl in isopropanol was added before 
the plates were shaken on an orbital shaker for 1 h at room 
temperature to facilitate formazan crystal solubilization. 
the absorbance was measured at 590 nm on a microtiter 
plate reader (thermomax Molecular Devices, nJ, USa). 
the percentage of viability was calculated as the a590 nm 
of peptide-treated cells relative to the negative control 
(100 % living cells) and expressed as a 50 % inhibitory 
concentration (IC50).
ltX-315 kinetics study
the kill kinetics of ltX-315 against B16F1 melanoma 
cells was studied using the IC100 concentration of ltX-315 
(35 μM, after 1 h). Cells were washed once with serum-
free rPMI 1640 before being incubated with peptide solu-
tion for 5, 15, 30, 45, 60, 90 and 120 min. after incubation 
with peptide, the cells were washed once and further incu-
bated for 2 h with serum-free rPMI 1640 containing 10 % 
Mtt.
ltX-315 versus cytostatica
ltX-315 and the different cytostatic drugs were dissolved 
in serum-free rPMI 1640 to a concentration range of 
7–100 μM (ltX-315) and 10–100 μM (cytostatic drugs), 
respectively. the cytostatic drugs were originally dissolved 
in dimethyl sulfoxide (DMSO) and later in serum-free 
rPMI 1640, yielding a final DMSO concentration ranging 
from 0.5 % in the 100 μM solution to 0.05 % in the 10 μM 
solution. Cells were washed once with serum-free rPMI 
1640 before being incubated with the peptide solutions or 
cytostatic drugs for 2, 4, 8, 24 and 48 h, respectively.
Hemolytic activity
Freshly isolated human red blood cells (hrBCs), prepared 
as previously described [23], were incubated for 1 h at 
37 °C with ltX-315 dissolved in PBS at concentrations 
ranging from 0.7 to 695 μM. the samples were centrifuged 
at 2,000 g for 5 min before the absorbance of the superna-
tant (S) was measured at 405 nm by a spectrophotometric 
microtiter plate reader (thermomax Molecular Devices, 
nJ, USa). the 0 and 100 % hemolysis controls consisted 
of hrBCs treated with PBS and 0.1 % triton X-100 in 
PBS, respectively.
release of high mobility group box-1 protein (HMgB1) 
from B16F1 cells
Murine B16F1 cells (3 × 105/well) were seeded in a 6-well 
plate, treated with either 35 μM ltX-315 (IC100) or 35 μM 
ltX-328 and incubated at 37 °C at 5 % CO2 and >95 % 
humidity for different time points (5–60 min). Serum-free 
rPMI 1640 was used as a negative control. Supernatants 
were collected after centrifugation at 1,400 g for 5 min and 
up-concentrated using amicon Ultra-0.5 Centrifugal Fil-
ter units with Ultracel-50 membrane (Millipore, norway). 
Cell lysates were washed with serum-free rPMI-1640 and 
collected in a Mastermix containing a 2× nuPage lDS 
Sample buffer (Invitrogen, norway), a 1× nuPage Sam-
ple reducing agent (Invitrogen, norway) and 50 % sterile 
H2O. Supernatants and cell lysates were boiled in a reduc-
ing nuPage lDS sample buffer, resolved on nuPage 
novex 4–12 % Bis–tris gels and electrotransferred onto 
a polyvinylidene difluoride (PVDF) membrane (Milli-
pore, norway). Membranes were hybridized with HMgB1 
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antibody (rabbit polyclonal to HMgB1—ChIP grade, 
abcam, UK), followed by horseradish peroxidase (HrP)-
conjugated secondary antibody (goat polyclonal anti-rabbit 
Igg, abcam, UK) and developed by Western blot luminol 
reagent (Santa Cruz Biotechnology, USa) according to the 
manufacturer’s instructions.
animals
Female C57Bl/6 wild-type mice, 5–6 weeks old, were 
obtained from Charles river, United Kingdom. all mice 
were housed in cages in a pathogen-free animal facil-
ity according to local and european ethical Committee 
guidelines.
tumor treatment
tumor cells were harvested, washed in rPMI-1640 and 
injected intradermally (i.d.) into the right side of the 
abdomen in C57Bl/6 mice (5 × 104 B16F1 cells per 
mouse/50 μl rPMI-1640). Palpable tumors (20–30 mm2) 
were injected i.t. with single doses of ltX-315 or ltX-
328 dissolved in saline (1.0 mg peptide/50 μl saline) once 
a day for 3 consecutive days, and the vehicle control was 
saline only (0.9 % naCl in sterile H2O). tumor size was 
measured using an electronic caliper and expressed as the 
area of an ellipse [(maximum dimension/2) × (minimum 
dimension/2) × π]. animals were then euthanized when 
the product of the perpendicular tumor dimensions reached 
130 mm2 or when tumor ulceration developed.
Histological examination
tissues were fixated by perfusion fixation using 4 % para-
formaldehyde. Following fixation and paraffin embedding, 
tissue sections were deparaffinized in xylene and graded 
alcohols, before being hydrated and washed with PBS. 
after antigen retrieval in a sodium citrate buffer (pH 6) in 
a microwave oven, the endogenous peroxidase was blocked 
by 0.3 % H2O2 for 15 min. Sections were then incubated 
overnight at 4 °C with a primary antibody (rabbit anti-CD3; 
Dako). as a secondary antibody, an anti-rabbit-HrP Super-
Picture Polymer detection kit was used (Invitrogen, San 
Francisco, Ca, USa). a matched isotype control was fur-
ther used as a control for non-specific background staining. 
a routine standard staining was performed with hematoxy-
lin and eosin.
mrna analysis using reverse transcriptase quantitative 
PCr
B16 melanoma tumor tissue was harvested at selected time 
points (4, 24, 48 and 120 h) following a single i.t. injection 
of either ltX-315 (1 mg) or the vehicle control. animals 
were euthanized using CO2 gas, and tumor tissue was 
harvested and put on allprotect tissue reagent (Qiagen, 
Hilden, germany) and left overnight at 4 °C. Samples were 
later stored at −20 °C until use.
total rna was extracted from the tumors using the 
rneasy Plus Universal Mini kit (Qiagen, Hilden, ger-
many), and on-column Dnase treatment of the rna 
samples was performed using rnase-Free Dnase (Qia-
gen, Hilden, germany) according to the manufacturer’s 
instructions. the quantity and purity of the extracted rna 
were determined using the nanoDrop spectrophotometer 
(thermo Fisher Scientific, Wilmington, De, USa), while 
the integrity of rna was checked by the experion auto-
mated electrophoresis system from Bio-rad.
the mrna expression levels in the tumors were quan-
tified by reverse transcription quantitative PCr (rt-qPCr) 
performed on a Stratagene Mx3000P instrument (Strata-
gene, la Jolla, Ca, USa). a reverse transcription of total 
rna was performed using the Quantitect reverse tran-
scription Kit (Qiagen, Hilden, germany) with 1 μg of rna 
per 20 μl cDna reaction. cDna corresponding to 10 ng 
rna was amplified for 40 cycles in a 25-μl PCr mix (Bril-
liant II SYBr® green low rOX QPCr Master Mix, agi-
lent technologies, Santa Clara, Ca, USa) containing a 
final concentration of 240 nM (for Il1 β, Il6, Il18, tnF-α, 
gaPDH and aCt-B) and 400 nM (for Il2 and IFn-γ) of 
each primer (Supplementary table 1). Cycling conditions 
were as follows: 95 °C for 10 min, 40 cycles at 95 °C for 
30 s, 55 °C for 1 min, 72 °C for 30 s and 1 cycle at 95 °C for 
1 min. Primer specificities and an absence of primer dimers 
were determined by the use of a SYBr green melting curve 
analysis. Duplicate reverse transcriptase reactions were per-
formed for each rna sample, and a duplicate PCr analy-
sis was performed for each cDna sample. the absence of 
genomic Dna was confirmed by performing a no reverse 
transcriptase (nort) control for randomly selected rna 
samples, and the absence of contaminations was assessed 
by including a no template control (ntC) in every run. 
the ΔΔCt method [35] was used to determine the relative 
amount of target genes, normalizing against the average 
expression of the two reference genes, gaPDH and aCt-B.
elISa analysis of plasma
Blood from C57Bl/6 mice with palpable tumors was har-
vested at selected time points (4, 24, 48 and 120 h) follow-
ing a single i.t. injection of either ltX-315 (1 mg) or the 
vehicle control. the blood was transferred to a MiniCollect 
eDta-K2 (Fisher Scientific) 0.5-ml tube and kept on ice 
before being centrifuged at 1,000 g for 10 min. Plasma was 
analyzed for Il1 β/Il1 F2 and Il6 using the Quantikine® 
elISa from r&D Systems.
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Secondary tumor challenge
animals with a complete regression (Cr) of tumor after 
ltX-315 treatment were given a second i.d. tumor cell chal-
lenge (5 × 104 B16F1 cells) on the left-hand side of the 
abdomen (contralateral to the first tumor site) 4–5 weeks 
after they were cured by ltX-315. animals surviving the 
i.d. tumor re-challenge were later given a second tumor re-
challenge intravenously (i.v.) (2 × 105 cells) through the tail 
vein. lungs were harvested on day 19 after the i.v. re-chal-
lenge. all mice were monitored for tumor size and survival.
Statistical analysis
all data represent at least three independent experiments 
and are expressed as the mean ± the standard deviation 
(SD) or the standard error of mean (SeM). animal sur-
vival curves (Kaplan–Meier Plot) were compared using a 
log-rank (Mantel-Cox) test. real-time PCr data were com-
pared using one-way anOVa and a tukey’s multiple com-
parison test, and we considered p values ≤0.05 to indicate 
statistical significance.
Results
Malignant melanoma cells are more sensitive to ltX-315 
compared to non-malignant cells
the cytotoxicity of ltX-315 was examined against a panel 
of murine and human melanoma cell lines and untrans-
formed cell lines using the Mtt assay [34]. ltX-315 exhib-
ited a twofold higher activity toward the three melanoma cell 
lines, B16F1 (murine), Fem-X and a375 (human) compared 
to normal human fibroblasts (MrC-5) and endothelial cells 
(HUV-eC-C). the peptide exhibited a slightly higher cyto-
toxicity toward human melanoma cells (a375) than normal 
human primary melanocytes (PCS-200-013). there was no 
detectable IC50 hemolytic activity by ltX-315 within the 
concentration range tested. the nonapeptide ltX-328 is a 
non-lytic control peptide that was used as a control peptide 
to ltX-315. no cytotoxic activity was observed for ltX-
328 against B16F1 melanoma cells (Fig. 1a).
ltX-315 rapidly kills B16 melanoma cells in vitro
the kill kinetics of ltX-315 against B16F1 melanoma 
cells was studied by treating B16F1 cells with ltX-315 for 
different time points. Figure 1b shows that the peptide lyses 
B16F1 cells within 15 min of treatment. at 30 min post-
treatment, nearly all cells were dead, thereby demonstrat-
ing a rapid lytic mode of action for ltX-315 against B16 
melanoma cells.
ltX-315 displays rapid kill kinetics compared 
to conventional chemotherapeutics
the cytotoxic effect of ltX-315 was compared with com-
monly used chemotherapeutic drugs against melanoma 
(dacarbazine, temozolomide and cisplatin), using the Mtt 
assay. ltX-315 exhibited a more rapid cytotoxic effect 
against both murine and human melanoma cells (B16F1 
and a375, respectively) compared to the chemotherapeu-
tic drugs, as shown by an IC50 value of 13 μM (B16F1) 
and 11 μM (a375) 2 h post-peptide treatment, compared to 
>100 μM for all the chemotherapeutics. a significant anti-
cancer effect was first observed after 24 h for the chemo-
therapeutic drugs (Fig. 1c).
B16F1 melanoma cells treated with ltX-315 in vitro 
release high mobility group box-1 (HMgB1)
to study whether ltX-315 was able to induce the 
release of danger-associated molecular pattern mol-
ecules (DaMPs), which is one of the requirements for 
immunogenic cell death, the release of HMgB1 from 
ltX-315- and ltX-328-treated B16F1 melanoma cells 
was measured using Western blot. B16F1 cells were 
treated with 35 μM of either ltX-315 or ltX-328, and 
the translocation of HMgB1 (normally expressed within 
the nucleus) from the lysate (l) to the supernatant (S) 
was assessed. Melanoma cells treated with ltX-315 
showed a gradual translocation of HMgB1 from the 
lysate to the supernatant after peptide treatment, with 
an increasing concentration in the supernatant as time 
progressed. after 30 min of treatment with ltX-315, 
most of the HMgB1 was released into the supernatant. 
Untreated control cells and cells treated with ltX-328 
showed no translocation of HMgB1, and the protein was 
retained within the lysates during the entire incubation 
period (Fig. 2).
ltX-315 induces complete regression of palpable B16F1 
tumors following intratumoral injection
to investigate the therapeutic potential of ltX-315, 
C57Bl/6 mice with B16 melanomas were injected i.t. 
with 50 μl of either vehicle (n = 8), 20 mg/ml ltX-315 
(n = 37) or ltX-328 (n = 8) for three consecutive days. 
In the control group and ltX-328 group, tumors developed 
rapidly and animals had to be euthanized due to the tumor 
burden (130 mm2) within 25 days after tumor challenge. 
tumor growth was not affected by injections with either the 
vehicle or ltX-328. In the ltX-315-treated group, com-
plete regression (Cr) of tumor tissue was observed in most 
animals (Fig. 3). the median survival was >50 days for 
ltX-315-treated animals, compared to 20 and 20.5 days 
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for saline and ltX-328-injected animals, respectively. at 
the end of study (50 days post-tumor challenge), 30 out of 
the 37 animals treated with ltX-315 had Cr. treatment 
with ltX-315 induced rapid tumor cell lysis, which was 
seen as a visible necrotic tumor area 24 h after the first i.t. 




a Inhibitory concentration killing 50% of the cells.
b IC50 above maximum concentration tested.
Data from three or more experiments are presented as mean ± SD.
Cell line LTX-315 IC50a ± SD (µM) LTX-328 IC50a ± SD (µM)
B16F1 13.3 ± 0.4 >350b
A375 12.7 ± 2.7
Fem-X 15.3 ± 2.1
PCS-200-013 19.0 ± 5.7
MRC-5 25.8 ± 2.0
HUV-EC-C 27.6 ± 3.3
RBC >695b
Fig. 1  In vitro cytotoxicity of ltX-315, B16 melanoma cell cytocide 
kinetics and in vitro cytotoxicity of ltX-315 versus chemotherapeu-
tic drugs. the in vitro cytotoxicity of ltX-315 and ltX-328 against 
a selection of cancer cell lines and normal cell lines (a). Cell killing 
kinetics of ltX-315 (IC100) against B16F1 melanoma cells (b) after 
designated time points (5, 15, 30, 45, 60, 90 and 120 min). IC100 of 
ltX-315 = 35 μM. In vitro cytotoxicity data demonstrating IC50 val-
ues of ltX-315 (red line) and three different chemotherapeutic drugs 
(c), dacarbazine (filled squares), temozolomide (filled triangles) and 
cisplatin (filled reverse triangles) after designated time points (2, 4, 
8, 24 and 48 h). the four compounds were tested against a murine 
B16F1 and a human a375 melanoma cell line. Data from three exper-
iments are presented for each time point as mean ± SeM
Fig. 2  ltX-315 treatment leads to extracellular release of HMgB1 
protein. B16F1 melanoma cells were treated in vitro with 35 μM of 
either ltX-315 (top) or ltX-328 (bottom) for selected time points 
(5–60 min). the translocation of the HMgB1 protein from the lysate 
(l) to the supernatant (S) was shown using Western blot. Control 
cells showed no translocation after 60 min. the figure is a digital 
image of a representative blot of three experiments
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Intratumoral treatment with ltX-315 stimulates t cell 
infiltration
In order to assess histological changes following local 
injection with ltX-315, tumors were perfusion fixated and 
surgically excised from animals (n = 2) after a single i.t. 
injection of vehicle (controls) or 1 mg ltX-315 at selected 
time points (4, 24, 48 and 120 h). a histological examina-
tion of the tumors revealed that i.t. injection of ltX-315 
induced an extensive necrosis of the tumor tissue, followed 
by a massive infiltration of lymphocytes into both the sur-
rounding connective tissue and the tumor parenchyma 
(Fig. 4b, d). Immunolabeling with anti-CD3 showed that 
many of the infiltrating cells were CD3+ t cells (Fig. 4f, 
h), whereas tumors injected with vehicle exhibited a viable 
tissue with no necrosis and a low number of lymphocytes 
(Fig. 4a, c, e, g).
Intratumoral treatment with ltX-315 mounts  
an inflammatory response in B16 tumors
to elucidate the mechanism behind the inflammatory 
response induced by ltX-315 in vivo and investigate the 
potential immune-modulating properties of the peptide, 
B16 melanomas treated with a single i.t. injection of vehi-
cle (controls) or 1 mg of ltX-315 (peptide treated) were 
harvested from animals (n = 3) at selected time points (4, 
24, 48 and 120 h). tumor tissue was analyzed for rela-
tive mrna expression of a panel of different cytokines 
(Il1 β, Il2, Il6, Il18, tnF-α and IFn-γ, Supplemen-
tary table 1). as early as after 4 h, an increased expres-
sion of the pro-inflammatory cytokines Il1 β and Il6 was 
evident, which was significantly upregulated compared 
to the controls injected with the vehicle. a certain incre-
ment in the expression of Il1 β was also seen after 48 h. 
Moreover, Il18 exhibited an increased mrna expression 
in ltX-315-treated tumors 120 h post-injection (Fig. 5a). 
ltX-315-treated tumors did not show an increased mrna 
expression of Il2, tnF-α and IFn-γ compared to vehicle-
injected control tumors (data not shown).
elISa analysis of plasma
to analyze for pro-inflammatory cytokines in animals 
injected with either a single injection of ltX-315 (n = 4) 
or the vehicle control, (n = 2) plasma was harvested from 
animals at selected time points (4, 24, 48 and 120 h). the 
plasma was analyzed for Il1 β and Il6. an increased level 
of Il6 was observed in the plasma 4 h after treatment with 
ltX-315 compared to vehicle controls (Fig. 5b). ltX-315-
treated animals did not show an increased level of Il1 β 
Fig. 3  effect of ltX-315 treatment on tumor growth of murine B16 
melanomas. Palpable melanoma tumors syngeneic with C57Bl/6 
mice were injected intratumorally with sterile 0.9 % naCl (vehicle 
controls) (a), with 1 mg ltX-328 (b), or with 1 mg ltX-315 (c) 
once per day on day 12, 13 and 14 after tumor challenge. the survival 
curves (d) were analyzed using a log-rank (Mantel-Cox) test and 
were shown to be significantly different (p = 0.0005)
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in the plasma compared to vehicle-injected control tumors 
(data not shown).
ltX-315 treatment of B16 melanomas induces protective 
immune responses
to examine whether treatment with ltX-315 was able 
to induce adaptive immune responses, cured animals 
(n = 25), together with non-treated control animals 
(n = 6), were re-challenged with 5 × 104 viable tumor 
cells i.d. on the abdomen contralateral to the first tumor 
site 4–5 weeks after Cr was attained. animals achiev-
ing Cr following the i.d. tumor re-challenge were later 
re-challenged a second time i.v. the majority of ani-
mals cured by ltX-315 showed growth inhibition, and 
tumor growth was absent in 15 out of the 25 animals, 
while all the control animals developed tumors subse-
quent of i.d. re-challenge (Fig. 6c). animals previously 
cured by ltX-315 i.t. injections (n = 7) showed systemic 
immune protection against B16 melanomas following i.v. 
Fig. 4  Intratumoral treat-
ment with ltX-315 induces 
immune cell infiltration. B16 
tumors were surgically excised 
24 h and 120 h post-injection 
with vehicle (a, c, e and g) 
or ltX-315 (b, d, f and h). 
tumors injected with ltX-315 
exhibited tumor tissue necrosis 
(N) and immune cell infiltration 
24 h post-injection (b) with an 
increased cell infiltration 120 h 
post-treatment (d), compared 
to viable controls (a and c). 
Immunolabeling with anti-CD3 
showed many of the infiltrat-
ing cells to be CD3+ t cells (f 
and h), compared to low- or 
non-infiltrated control tumors (e 
and g). the arrows point to the 
remaining viable tumor tissue 
in treated tumors. Histological 
examinations were performed 
by H&e staining and anti-CD3 
immunolabeling at ×200
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re-challenge (Fig. 6d, e), compared to non-treated control 
animals (n = 7). ltX-315-cured animals (mean # tumor 
foci = 15.86) displayed a significantly lower number of 
lung tumor foci compared to non-treated control animals 
(mean # tumor foci = 123.3). additionally, histological 
examinations revealed that the lung tumor foci of ani-
mals previously cured by ltX-315 were significantly 
more infiltrated by CD3+ t cells, compared to the less 
infiltrated lung tumor foci of non-treated control animals 
(Fig. 6f).
Discussion
Cationic antimicrobial peptides have been studied since 
the 1960s [36, 37] and in later years have received added 
attention for their therapeutic potential against cancer [9–
11]. Our group has previously shown that CaPs such as 
lfcinB can induce complete tumor regression following 
the i.t. treatment of syngeneic tumors in mouse models [23] 
and tumor growth inhibition in a human xenograft model 
[24]. through Sar studies on lfcinB derivatives, we were 
able to synthesize shorter and more effective CaPs with an 
improved anticancer activity, both in vitro and in vivo [28–
32]. ltX-315 was designed as a helical CaP optimized for 
membrane destabilization to be used for the local treatment 
of solid tumors.
Previous studies have shown that naturally occurring 
CaPs such as the cell-penetrating peptide, crotamine, 
display potent cytotoxic activity against B16 melanoma 
cells in vitro as well as B16 melanomas established in 
syngeneic mice [38]. In the present study, the antitumor 
effect of ltX-315 against the highly aggressive and low 
immunogenic B16 melanoma cell line [39] was studied. 
In vitro results revealed that ltX-315 was highly active 
against both murine and human melanoma cell lines. 
all the cancer cell lines were more sensitive to ltX-
315 compared to normal human fibroblasts (MrC-5) 
and endothelial cells (HUV-eC-C). In accordance with 
studies on other CaPs, the specificity of ltX-315 for 
Fig. 5  Intratumoral treatment with ltX-315 induces an inflammatory 
response. Following a single i.t. injection of sterile 0.9 % naCl (con-
trol), or with 1 mg ltX-315, tumor tissue (a) and  plasma (b) were 
harvested 4, 24, 48 and 120 h post-injection and analyzed for mrna 
expression of several different cytokines using rt qPCr (tumor tis-
sue) or for cytokine content using elISa (plasma). Data from three 
animals are presented for each time point as mean ± SeM. normal 
tumor expression (control) was defined as 1 (normal expression = 
normal/normal), while treated tumor expression was defined as treated 
tumor = treated tumor/normal (a). Statistical analysis was performed 
using a tukey′s multiple comparison test (p < 0.05). Data from 
animals treated with either ltX-315 (n = 4) and vehicle (n = 2) are 
presented as the pg/ml content of Il6 in pooled plasma samples (b)
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tumor cells is probably due to differences in cell mem-
brane composition between cancer cells and non-malig-
nant cells. Cancer cells have been shown to have a larger 
quantity of anionic molecules on their membrane [13, 14, 
16], in addition to an increased membrane fluidity [17, 
18] and membrane cell surface due to more microvilli 
[19, 20]. the cytotoxicity of ltX-315 was somewhat 
similar toward human melanoma cells (a375) and nor-
mal human primary melanocytes (PCS-200-013). How-
ever, since ltX-315 is designed for intratumoral treat-
ment, the selectivity of the peptide is of less significance 
compared to drugs used systemically. locally delivered 
cytotoxic drugs have been shown to increase cancer 
cell killing and improve clinical responses, in addition 
to minimize patient toxicity, compared to systemically 
delivered drugs [40]. ltX-315 did not display any IC50 
cytotoxic activity against hrBCs (Fig. 1a). red blood 
cell membranes are neutral due to their high content of 
neutral phospholipids such as sphingomyelin and phos-
phatidylcholine [41], demonstrating that ltX-315 is 
membrane-specific. ltX-315 induced the rapid killing of 
B16F1 and a375 cells compared to conventional chemo-
therapeutics (Fig. 1b, c), which kill cells by interfering 
with Dna replication or structure [42–44].
B16F1 cells treated with ltX-315 in vitro released 
HMgB1 from the inside of the cells to the cell super-
natant (Fig. 2), where it can act as a DaMP. DaMPs are 
able to stimulate the maturation of dendritic cells (DCs), 
thereby leading to an enhancement of responses from 
CD8+ t cells [45, 46]. normally in the nuclear compart-
ment, when released into the extracellular environment, 
HMgB1 has been reported to be involved in the recruit-
ment of inflammatory cells [47] and the promotion of 
natural killer (nK) cells, including monocyte interac-
tions, DC maturation [48] and the increase of IFn-γ 
release by nK cells [49]. By inducing necrotic cell 
death, ltX-315 is capable of stimulating the immune 
system due to the release of DaMPs, thus leading to an 
inflammatory reaction. a failure to induce the release 
of DaMPs will not stimulate the immune system, and 
potential cellular death will therefore be non-immuno-
genic [46].
Fig. 6  ltX-315 treatment induces immune protection against B16 
melanomas. tumor growth in non-treated control animals (a) was 
compared to animals previously cured by ltX-315 treatment (b 
and d). animals were re-challenged intradermally with 5 × 104 
viable B16F1 cells contralateral to the first tumor site (b) or intra-
venously with 2 × 105 viable B16F1 cells (d). the survival curves 
of animals re-challenged intradermally (c) were analyzed using a 
log-rank (Mantel-Cox) test and were shown to be significantly dif-
ferent (p < 0.0001). the number of lung tumor foci was analyzed 
using an unpaired t test and was shown to be significantly different 
(p = 0.003) when comparing intravenously re-challenged animals 
previously cured by ltX-315 with non-treated control animals (d). 
a digital image illustrates representative lungs from the different 
groups (e). the tumor foci of animals previously cured by ltX-315 
were highly infiltrated by CD3+ t cells compared to control animals 
as shown by immunolabeling with anti-CD3 (f)
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the anticancer effect of ltX-315 was examined in a 
mouse melanoma model through the i.t. injection of intra-
dermal B16 tumors. a majority of the animals treated with 
ltX-315 experienced a complete and long-lasting tumor 
regression and were tumor-free 5 weeks post-treatment 
(Fig. 3). a histological examination revealed that ltX-315 
induced extensive hemorrhagic necrosis of the tumor paren-
chyma and massive infiltration of lymphocytes. Immuno-
labeling with anti-CD3 showed that a major portion of the 
infiltrating immune cells were t cells (Fig. 4), indicating 
that ltX-315 induces a cell death that leads to an increase 
in the number of tumor-infiltrating lymphocytes (tIls).
the presence of an inflammatory response in the B16 
melanomas treated with ltX-315 was further indicated 
by increased mrna levels of inflammatory cytokines 
such as interleukin (Il) 1β, Il6 and Il18 in the tumor tis-
sue and of Il6 in plasma samples. expression of Il1 β and 
Il6 was augmented in ltX-315-treated tumors compared 
to vehicle-injected tumors (p < 0.05), and there were also 
indications of an increased expression of Il18 in peptide-
treated tumors compared to control tumors (not signifi-
cant) (Fig. 5a). there was a fivefold increase of Il6 in the 
plasma of animals injected with ltX-315 compared to 
vehicle-injected control animals 4 h post-injection. Il1 β 
has been shown to promote the infiltration of inflammatory 
and immunocompetent cells, function as a co-stimulator of 
t cell functions (usually together with an antigen or a mito-
gen) and play a role in antibody production from B cells 
[50, 51]. Interleukin 6 is involved in acute inflammation 
following tissue trauma or damage, in tH17 cell induction 
and differentiation and in B cell proliferation and antibody 
production [50, 52, 53]. Interleukin 18 is involved in both 
innate and adaptive immune responses such as inflamma-
tion, modulates the activity of tH1 cells, inhibits angio-
genesis and has chemoattractant properties for polymor-
phonuclear cells [50, 54–57]. the upregulation of these 
cytokines demonstrates that local treatment of B16 melano-
mas with ltX-315 stimulates a pro-inflammatory response 
and an activation of the immune system. We did not detect 
increased mrna levels for tnF-α and IFn-γ in ltX-
315-treated tumors compared to vehicle-injected tumors. 
Cytokine gene expression is tightly regulated, and the 
mrnas for most cytokines have been shown to have a very 
short half-life [58]. tnF-α mrna is normally degraded 
within minutes and therefore often difficult to detect.
to investigate whether the immune-modulating prop-
erties of ltX-315 in vivo led to a long-term protective 
immune response, animals were re-challenged with live 
tumor cells. all previously cured animals demonstrated 
significant tumor growth inhibition and no tumor take 
was observed in 60 % of the animals given viable cells 
i.d. (Fig. 6a–c). animals surviving the i.d. re-challenge 
were re-challenged with viable B16 melanoma cells i.v. 
9 months post-ltX-315 treatment to examine a possible 
long-lasting systemic protection against the cancer and its 
effect in an experimental lung metastasis model. all ani-
mals re-challenged i.v. demonstrated systemic immune 
protection against B16 melanomas compared to non-treated 
control animals (Fig. 6d, e) in addition to an increase in the 
amount of infiltrating CD3+ t cells into the re-challenged 
lung tumor foci, as seen by immunolabeling with anti-CD3 
(Fig. 6f). this indicates that ltX-315 induced systemic 
antitumor immune responses, with the persistence of a t 
cell-mediated antitumor immunity and thus a long-term 
protection against relapse of the tumor and against lung 
tumor foci. Berge et al. [28] have previously shown that the 
immune protection is transferrable between animals using 
adoptive transfer techniques, after i.t. treatment of synge-
neic a20 lymphomas with a peptide analog to ltX-315, 
named ltX-302, demonstrating that the immune protection 
is t cell dependent. the mechanism of ltX-315 is thought 
to be similar to that of ltX-302, by inducing long-term, 
specific cellular immunity against B16 melanomas through 
membrane-induced lysis and the extracellular release of 
DaMPs (HMgB1). this ltX-315-induced immunogenic 
cell death potentially results in the maturation of antigen-
presenting cells such as DCs and a subsequent presentation 
of tumor antigens to t cells, creating specific cytotoxic t 
cells capable of eradicating residual cancer cells.
taken together, our observations in vitro and in vivo indi-
cate that i.t. administration of ltX-315 leads to extensive 
tumor necrosis initiated by a direct disruptive effect of the 
peptide on the plasma membrane of tumor cells. Moreover, 
the necrotic effect of ltX-315 leads to the release of DaMPs 
that stimulates immune responses and the infiltration of tIls 
into the tumor parenchyma, which may be critical in the erad-
ication of solid B16 melanomas due to their possible role in 
inducing a long-lasting tumor immune protection.
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